FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma – Lymphoma News Today
Lymphoma News Today |
FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma
Lymphoma News Today Axicabtagene ciloleucel is a CAR (chimeric antigen receptor) T–cell therapy that removes the patient’s own T–cells and genetically engineers them to express a receptor that recognizes the CD19 protein, found at the surface of most lymphoma cells. Kite Pharma Inc Receives a Buy from FBR CapitalAnalyst Ratings |
Genetic Literacy Project |
Age-related macular degeneration may be treatable using viral injection gene therapy
Genetic Literacy Project [R]esearchers from Johns Hopkins Medicine were looking for ways to treat a particular type of age-related macular degeneration (AMD) known as a wet AMD. It’s a rare and more severe form of the disease [that] causes new blood vessels to grow under the … |
CBS News |
FDA approves expanded uses for immunotherapy
CBS News May 30, 2017, 8:12 AM | The FDA expanded the approved uses for an immunotherapy drug that has successfully treated certain lung cancers and melanoma. The treatment that triggers the body’s own defense system to fight cancer was used by former … Keytruda drug treats cancer based on tumor’s genetics rather than its locationGenetic Literacy Project |
Devon Live |
Baby Max can only survive with a constant supply of stem cells
Devon Live A Devon family are swimming to Great Ormond Street Hospital to help a mum whose 15-month-old son has been diagnosed with very rare syndrome called Diskeratosis Congenita. Little Max Hilton’s treatment is reliant on a steady supply of stem cell donors … |
|
Abeona Therapeutics Receives Rare Pediatric Disease Designation …
GlobeNewswire (press release) Abeona’s Third Gene Therapy Program to Receive Rare Pediatric Disease Designation, expected to enable Priority Review Voucher. |